



ASOP Global Highlights Policy Momentum, Media Engagement and Patient Safety Efforts

The [Alliance for Safe Online Pharmacies](#) (ASOP Global) continues to advance efforts to protect patients from illegal online drug sellers, counterfeit medicines and unsafe online prescribing and compounding practices. Recent work has focused on regulatory engagement, bipartisan policy action, media outreach and patient education. See below for the latest updates:

Urging FDA Action on Compounded GLP-1s

ASOP Global recently [urged](#) the U.S. Food and Drug Administration (FDA) to reject nominations of semaglutide, tirzepatide and liraglutide for inclusion on the agency's 503B Bulks List.

ASOP Global warned that allowing large-scale compounding of these drugs from bulk substances could further fuel a risky online marketplace for unapproved GLP-1 products. The [ASOP Global Foundation's 2025 Consumer Behavior Survey](#) found that 77% of GLP-1 users falsely believe compounded medications are evaluated by FDA for safety and efficacy, rising to 86% among those who obtain GLP-1s through an online provider.

Read the comments [here](#).

Raising Concerns Following FDA Advisory Committee Peptide Votes

ASOP Global [pushed back](#) on claims that expanding legal compounding would reduce demand for gray-market peptides, warning that it is "wishful thinking" to believe a regulated market alone will make illegal sellers disappear.

Without stronger federal and state authorities and, critically, meaningful enforcement, illegal actors can simply masquerade as legitimate compounders, increasing confusion and risk for patients. ASOP Global raised these concerns after the FDA's Pharmacy Compounding Advisory Committee recommended adding six peptide substances to the Section 503A Bulk Drug Substances List despite insufficient evidence regarding their safety and effectiveness.

ASOP Global continues to urge FDA to follow the evidence and prioritize patient safety as it considers the Committee's nonbinding recommendations.

Read the full statement [here](#).

Senate Progress on the SAFE Drugs Act

ASOP Global Board Chair Leigh Verbois was quoted in Senator Jim Banks' [announcement](#) highlighting the Senate Health, Education, Labor and Pensions Committee's advancement of the bipartisan SAFE Drugs Act. Verbois thanked Senators Banks and Martin Heinrich for their leadership and emphasized that the legislation would help close loopholes that allow unsafe, unapproved medicines to reach patients, including through illegal online sellers.

ASOP Global also applauded the Committee's advancement of the legislation, which would strengthen patient protections and increase transparency and oversight across the pharmacy compounding industry. The organization additionally welcomed the inclusion of an amendment aimed at preventing counterfeit, unapproved, misbranded and adulterated drugs and ingredients from entering the United States.

Read Senator Banks' announcement [here](#).

Read ASOP Global's full statement [here](#).

House Action on Illicit Drug Threats

ASOP Global also [commended](#) the House Energy and Commerce Health Subcommittee for advancing bipartisan legislation focused on counterfeit substances, fentanyl-related risks and the illegal use of pill press and encapsulating machines.

The bills include the PRESS Act, the Stop Pills That Kill Act and the Fight Illicit Pill Presses Act. Together, they would address key vulnerabilities in the illicit drug supply chain and strengthen efforts to protect patients.

Learn more [here](#).

ASOP Global Leaders Featured in Recent Media Coverage

ASOP Global leaders and advisors continue to serve as expert sources on emerging online drug safety issues:

- In [POLITICO Pro](#), ASOP Global Board Member Dan Burke discussed the enforcement challenges posed by illegal online sellers marketing unapproved retatrutide and other peptide products directly to consumers.
- *Personal Care Insights* also featured ASOP Global's perspective in two articles examining the FDA advisory committee's review of injectable peptides and the potential implications of its recommendations for gray-market sales, patient safety, and beauty-industry marketing:
 - [US FDA panel weighs injectable peptides as experts demand gray market guardrails](#)
 - [US FDA peptide decision could create marketing challenges for beauty industry](#)

- ASOP Global Senior Advisor Libby Baney Burstein was quoted in [Modern Healthcare](#) on employer drug cost-containment strategies and alternative funding programs (AFPs). She emphasized the patient safety risks of routing individuals into opaque programs or outside the regulated U.S. drug supply chain.



Advancing Patient Awareness Through Every Dose Matters

ASOP Global and its partners continue to promote patient education through the [Every Dose Matters campaign](#), which raises awareness about falsified cancer medicines and illegal online drug sellers.

The campaign offers resources to help patients and healthcare providers identify safe sources of medicines and understand the dangers of counterfeit drugs.

Learn more at EveryDoseMatters.org.



Join Us at ASOP Global All-Hands

ASOP Global will convene members and partners at the ASOP All-Hands Conference in Washington, D.C., and virtually on September 15-16.

The meeting will bring together leaders across patient safety, pharmacy, policy, technology and enforcement. The program will also include a preview of ASOP Global's forthcoming social media dashboard, developed with Dr. Tim Mackey, and a discussion of how emerging data can help identify risks tied to illegal online medication sources and misleading marketing.

For additional information, contact Maya.Bolter@FaegreDrinker.com.

Illegal online pharmacies and unsafe digital drug sellers remain a serious global public health threat. Through policy engagement, research, education, media outreach and coalition convenings, ASOP Global remains committed to protecting patients and ensuring safe access to medicines worldwide.

Learn more at buysaferx.pharmacy.